On the morning of March 17, the signing ceremony of strategic cooperation between Yangzijiang Pharmaceutical Group and Jiangsu Riko Biological was held at the Yangzijiang Academy of Taizhou headquarters, and the two sides announced that they would carry out all-round strategic cooperation in the fields of product research and development, clinical research and global business expansion. Ye Donghua, Vice mayor of Taizhou City, Secretary of Party Working Committee of Taizhou Pharmaceutical High-tech Zone and secretary of Gaogang District Party Committee attended the signing ceremony and made a speech. Xu Haoyu, Secretary of the Party Committee, Chairman and general manager of Yangzijiang Pharmaceutical Group, and Liu Yong, chairman and general manager of Jiangsu Ruike Biotechnology Co., Ltd. signed the strategic cooperation agreement on behalf of both parties.

Ye Donghua, on behalf of the district Party Working Committee Management Committee and the District Party Committee and district government, extended warm congratulations to the strategic cooperation between Yangzijiang Pharmaceutical Group and Jiangsu Ruike Biology. He said that the two companies are highly complementary and have a wide range of cooperation space in product research and development, marketing, capital operation and other fields. The strategic cooperation between the two sides is also an important achievement of the integrated development of the two regions, indicating that the two regions have accelerated from the integration of party and government institutions to the all-round integration of economic and social aspects. It is believed that through the demonstration of strategic cooperation between the two enterprises, it will drive more enterprises to cooperate, thereby boosting the formation of a chemical reaction of "1+1=1" in the two regions, constantly releasing the multiplier effect of "1+1 > 2", and the Party Committee and government will create the best environment to fully support enterprises to become bigger and stronger.

At the signing ceremony, Xu Haoyu said that Rueke Biology is deeply engaged in the field of new vaccine adjuvants and mRNA vaccines, has a core technology platform, has HPV vaccine, new coronavirus vaccine, recombinant herpes zoster vaccine, adult tuberculosis vaccine and other heavy product pipelines, and has obvious competitive advantages in research and development technology. At present, Yangzijiang Pharmaceutical Group is in a critical period of industrial transformation and upgrading. Strengthening regional linkage and realizing complementary advantages is of great significance to the long-term development of the enterprise. He hoped that the two sides will take the signing of the comprehensive strategic agreement as an opportunity to push cooperation to a wider, deeper and higher level and achieve common development.

Liu Yong said that Yangzijiang Pharmaceutical Group is the best partner of Rikco Biotechnology, and the two sides will further find the entry point for cooperation in various fields on the basis of deep mutual trust and close coordination, quickly enrich the connotation of strategic cooperation, establish advantages in the global market competition, and make greater contributions to the innovation and development of biomedicine and vaccines.

It is reported that Yangzijiang Pharmaceutical Group adheres to the strategic basis of research and development and innovation, promotes the "three drugs" of traditional Chinese medicine, chemical drugs and biological drugs, and continues to increase the research and development of biological drugs and industrial layout. The signing of the strategic cooperation agreement between the two sides has laid the foundation for the Group to better integrate the innovative resources, industrial resources and space resources related to the biological vaccine industry, as well as accelerate the integration process of the planning, construction, operation and management of the Group's biological drug industry, and comprehensively enhance the professional, market-oriented and international development level of the company.